The impact of p16(ink4a) positivity in invasive vulvar cancer on disease-free and disease-specific survival, a retrospective study

PURPOSE: To evaluate HPV and p16(ink4a) status as prognostic factors in patients with invasive vulvar cancer. METHODS: Retrospective analysis of disease-free (DFS) and disease-specific survival (DSS) of patients with invasive vulvar cancer at a single tertiary care center. Histology, HPV and p16(ink...

Descripción completa

Detalles Bibliográficos
Autores principales: Gensthaler, Lisa, Joura, Elmar A., Alemany, Laia, Horvat, Reinhard, de Sanjosé, Silvia, Pils, Sophie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Gynecologic Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060959/
https://www.ncbi.nlm.nih.gov/pubmed/31970493
http://dx.doi.org/10.1007/s00404-020-05431-7
_version_ 1783504320798392320
author Gensthaler, Lisa
Joura, Elmar A.
Alemany, Laia
Horvat, Reinhard
de Sanjosé, Silvia
Pils, Sophie
author_facet Gensthaler, Lisa
Joura, Elmar A.
Alemany, Laia
Horvat, Reinhard
de Sanjosé, Silvia
Pils, Sophie
author_sort Gensthaler, Lisa
collection PubMed
description PURPOSE: To evaluate HPV and p16(ink4a) status as prognostic factors in patients with invasive vulvar cancer. METHODS: Retrospective analysis of disease-free (DFS) and disease-specific survival (DSS) of patients with invasive vulvar cancer at a single tertiary care center. Histology, HPV and p16(ink4a) status were evaluated in the context of a global multicenter trial. Logistic regression models were performed to identify the impact of p16(ink4a) positivity. RESULTS: 135 patients were included in the analysis. 32 (23.7%) showed a p16(ink4a) expression of over 25%. Disease-free and disease-specific survival was longer in p16(ink4a) positive patients (23 vs. 10 months, p = 0.004, respectively, 29 vs. 21 months, p = 0.016). In multivariate analysis, p16(ink4a) positivity was an independent parameter for DFS (p = 0.025, HR: 2.120 (1.100–4.085)), but not for DSS (p = 0.926, HR: 1.029 (0.558–1.901), in contrast to age and tumor stage. CONCLUSIONS: Age and tumor stage negatively affect survival. However, disease-free survival is significantly longer in patients with p16(ink4a) positive invasive vulvar cancer.
format Online
Article
Text
id pubmed-7060959
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-70609592020-03-23 The impact of p16(ink4a) positivity in invasive vulvar cancer on disease-free and disease-specific survival, a retrospective study Gensthaler, Lisa Joura, Elmar A. Alemany, Laia Horvat, Reinhard de Sanjosé, Silvia Pils, Sophie Arch Gynecol Obstet Gynecologic Oncology PURPOSE: To evaluate HPV and p16(ink4a) status as prognostic factors in patients with invasive vulvar cancer. METHODS: Retrospective analysis of disease-free (DFS) and disease-specific survival (DSS) of patients with invasive vulvar cancer at a single tertiary care center. Histology, HPV and p16(ink4a) status were evaluated in the context of a global multicenter trial. Logistic regression models were performed to identify the impact of p16(ink4a) positivity. RESULTS: 135 patients were included in the analysis. 32 (23.7%) showed a p16(ink4a) expression of over 25%. Disease-free and disease-specific survival was longer in p16(ink4a) positive patients (23 vs. 10 months, p = 0.004, respectively, 29 vs. 21 months, p = 0.016). In multivariate analysis, p16(ink4a) positivity was an independent parameter for DFS (p = 0.025, HR: 2.120 (1.100–4.085)), but not for DSS (p = 0.926, HR: 1.029 (0.558–1.901), in contrast to age and tumor stage. CONCLUSIONS: Age and tumor stage negatively affect survival. However, disease-free survival is significantly longer in patients with p16(ink4a) positive invasive vulvar cancer. Springer Berlin Heidelberg 2020-01-22 2020 /pmc/articles/PMC7060959/ /pubmed/31970493 http://dx.doi.org/10.1007/s00404-020-05431-7 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Gynecologic Oncology
Gensthaler, Lisa
Joura, Elmar A.
Alemany, Laia
Horvat, Reinhard
de Sanjosé, Silvia
Pils, Sophie
The impact of p16(ink4a) positivity in invasive vulvar cancer on disease-free and disease-specific survival, a retrospective study
title The impact of p16(ink4a) positivity in invasive vulvar cancer on disease-free and disease-specific survival, a retrospective study
title_full The impact of p16(ink4a) positivity in invasive vulvar cancer on disease-free and disease-specific survival, a retrospective study
title_fullStr The impact of p16(ink4a) positivity in invasive vulvar cancer on disease-free and disease-specific survival, a retrospective study
title_full_unstemmed The impact of p16(ink4a) positivity in invasive vulvar cancer on disease-free and disease-specific survival, a retrospective study
title_short The impact of p16(ink4a) positivity in invasive vulvar cancer on disease-free and disease-specific survival, a retrospective study
title_sort impact of p16(ink4a) positivity in invasive vulvar cancer on disease-free and disease-specific survival, a retrospective study
topic Gynecologic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060959/
https://www.ncbi.nlm.nih.gov/pubmed/31970493
http://dx.doi.org/10.1007/s00404-020-05431-7
work_keys_str_mv AT gensthalerlisa theimpactofp16ink4apositivityininvasivevulvarcancerondiseasefreeanddiseasespecificsurvivalaretrospectivestudy
AT jouraelmara theimpactofp16ink4apositivityininvasivevulvarcancerondiseasefreeanddiseasespecificsurvivalaretrospectivestudy
AT alemanylaia theimpactofp16ink4apositivityininvasivevulvarcancerondiseasefreeanddiseasespecificsurvivalaretrospectivestudy
AT horvatreinhard theimpactofp16ink4apositivityininvasivevulvarcancerondiseasefreeanddiseasespecificsurvivalaretrospectivestudy
AT desanjosesilvia theimpactofp16ink4apositivityininvasivevulvarcancerondiseasefreeanddiseasespecificsurvivalaretrospectivestudy
AT pilssophie theimpactofp16ink4apositivityininvasivevulvarcancerondiseasefreeanddiseasespecificsurvivalaretrospectivestudy
AT gensthalerlisa impactofp16ink4apositivityininvasivevulvarcancerondiseasefreeanddiseasespecificsurvivalaretrospectivestudy
AT jouraelmara impactofp16ink4apositivityininvasivevulvarcancerondiseasefreeanddiseasespecificsurvivalaretrospectivestudy
AT alemanylaia impactofp16ink4apositivityininvasivevulvarcancerondiseasefreeanddiseasespecificsurvivalaretrospectivestudy
AT horvatreinhard impactofp16ink4apositivityininvasivevulvarcancerondiseasefreeanddiseasespecificsurvivalaretrospectivestudy
AT desanjosesilvia impactofp16ink4apositivityininvasivevulvarcancerondiseasefreeanddiseasespecificsurvivalaretrospectivestudy
AT pilssophie impactofp16ink4apositivityininvasivevulvarcancerondiseasefreeanddiseasespecificsurvivalaretrospectivestudy

Ejemplares similares